Aristotle University Of Thessaloniki (AUTH)
Συσχέτιση δεικτών φλεγμονής με την εμφάνιση και την πορεία κατάθλιψης σε ψωριασικούς ασθενείς πριν και μετά τη χορήγηση συστηματικής αγωγής
Abstract
dc:descriptionPsoriasis is a systemic disease of the skin and nails associated with a wide range of comorbidities such as depression, psoriatic arthritis and metabolic syndrome. The study aimed to examine a potential association between inflammatory markers: CRP, ESR, TNFa, IL-6, IL-23, IL-17A and depression in patients with psoriasis. The potential influence of a three-month systematic treatment for psoriasis on the inflammatory markers levels was also examined (Conventional systemic therapy, Biologics).A total of 80 individuals were enrolled in the study. Case participants included 28 patients diagnosed with Psoriasis (Beck Depression Inventory-II:≤17) and 24 patients diagnosed with Psoriasis and Depression (Beck Depression Inventory-II:>17). Twenty-eight (28) healthy participants comprised the control group. Psoriasis severity was evaluated by using Psoriasis Area and Severity Index, Physician Global Assessment, Body Surface Area and Dermatology Life Quality Index. Written approval was obtained for its use in this study: Cardiff University (09/2015). Other factors considered in the study were obesity using the Body Mass Index, the levels of stress using the Beck Anxiety Inventory, and the presence of insomnia using the Athens Insomnia Scale. Blood draws and inflammatory markers measurements were performed for all participants. The study examines the difference observed in CRP, ESR, TNFa, IL-6, IL-23 and IL-17A values among the three groups at baseline, as well as the changes observed within a period of three months in the two groups (psoriasis, psoriasis and depression). Both CRP and ESR levels were higher in the case group (i.e. Psoriasis and Depression and Psoriasis) compared to healthy controls. Furthermore, psoriatic patients with depression showed increased CRP and ESR levels compared to those of psoriatic patients without depression. The serum levels of IL-6 were significantly higher in the group of psoriatic patients with depression, compared to those with psoriasis without depression. Also, serum levels of IL-17A were higher in the group of psoriatic patients with depression. These results confirm the important role of IL-6 in the pathogenesis of depression among psoriatic patients. Instead, no significant changes in CRP, ESR, TNFa, IL-6, IL-23 and IL-17A values were observed between the two-time points (baseline and three months) after systemic therapy for psoriasis for the two groups of patients (Psoriasis and Depression and Psoriasis). We consider that the 3-month period between the two measurements was too short to allow safe conclusions on the possible reduction of inflammatory markers after systemic treatment for psoriasis that patients received. Conclusively, psoriasis is a disease requiring a multidimensional therapeutic approach. In depressed psoriatic patients should be given drugs whose mechanism of action leads to a decrease in IL-6 (e.g., anti-TNF, anti-IL17A). The increased value of IL-6 is probably related to the use of ciclosporin and apremilast. As a result, these drugs should be administered with caution to patients with psoriasis and depression. The evaluation of both CRP and ESR and their use to detect the presence of depression in patients with psoriasis can be an important tool for their holistic treatment of theirs.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Mitsiou, Eleni
- Μήτσιου, Ελένη
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56002